The financials
BillionToOne, Inc. by the numbers
BillionToOne, Inc. (BLLN) reported revenue of $108M in Q1 2026 (quarter ended Mar 31, 2026), up 84% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $18M (17% of revenue). For the full year FY2025, revenue was $305M (+100% year on year) and net income $7.5M. Its largest product in Jun 2026 was Prenatal at $94M, 86% of the disclosed total, well ahead of Oncology at 12%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $108M | $59M | +84% |
| Gross profit | $79M | $38M | +108% |
| Operating income | $18M | −$2.3M | to a profit |
| Net income | $18M | −$4.0M | to a profit |
| Diluted EPS | $0.34 | −$0.39 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Prenatal | $94M | 86% |
| Oncology | $14M | 12% |
| Clinical Trial Support And Other Services | $1.5M | 1.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $109.4M (+0.98%)
Oncology grew +176% year on yearPrenatal +55% year on year
Segment Latestquarter on quarteryear on year
- Prenatal$94.2M$94.2MQoQ -2.4%year on year +55%-2.4%+55%
- Oncology$13.7M$13.7MQoQ +27%year on year +176%+27%+176%
- Clinical Trial Support And Other Services$1.5M$1.5MQoQ +34%year on year +99%+34%+99%
Diagnostics & Research
The closest names by size in the same industry